ENDOVASCULAR  NEUROLOGIST  TO  SPEAK  ON  SPECIALIZED STROKE  TREATMENT  IN  McALLEN 

Breaking News
3454

Translate to Spanish or other 102 languages!

Mega Doctor News—

- Advertisement -

Dr. Ameer Hassan to Speak at Free “Dessert with the Doctor”

Tuesday, Nov. 11 at McAllen Public Library

McALLEN – Dr. Ameer Hassan, Endovascular Neurologist, will speak and answer questions on “Surviving a Stroke: Learn about Important Tools Available to Help Stop a Stroke from Progressing and Causing Permanent Disability”, during a free “Dessert with a Doctor” event on Tuesday, Nov. 11, at 6:30 p.m. at the McAllen Public Library, 4001 N. 23rd Street (just north of Nolana).   Dr. Hassan will also discuss specialized endovascular stroke treatment which can extend the window of time for care of stroke patients and reduce the chances of permanent disability.  The event is free and open to the public, and attendees are invited to enjoy a free heart-healthy dessert, compliments of Valley Baptist Medical Center.  For more information or to RSVP, please call 1-888-902-5433.

- Advertisement -

 

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Unprecedented $10 million Federal Grant will boost the Valley
Next article
Foster, Cigarroa, Reyes in full support for Vaquero and President Guy Bailey

More Articles

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Texas Oncology Expands Cancer Care With New McAllen West Clinic

Texas Oncology celebrated the grand opening of its McAllen West clinic Sept. 29, expanding cancer treatment, diagnostic, and research capabilities in the Rio Grande Valley as the organization continues its presence in the region, spanning more than 40 years.
- Advertisement -